pharmaceutical data scientists

Abstract: Understanding biomolecular function requires characterizing three-dimensional structure and conformational variability, for which cryogenic electron microscopy (cryo-EM) is a powerful tool. Cryo-EM produces noisy two-dimensional particle images in which molecular structure, particle pose, and imaging conditions are jointly encoded. Recovering biological information from these observations spans inverse problems including pose estimation, heterogeneity analysis, and reconstruction. These tasks are usually addressed independently despite shared protein structure and image formation, motivating a common representation across inverse problems. Since biologically meaningful differences may be spatially localized, we study self-distillation with complementary global and masked patch objectives. Because experimental dataset discrimination can reflect acquisition-specific cues, we develop controlled synthetic and experimental evaluations and find that structural discrimination benefits from dense spatial features. We introduce the EMber family of vision transformers, pre-trained on >50 million experimental particle images from 214 EMPIAR datasets together with simulated projections from 268,000 molecular assemblies. EMber improves upon existing methods at conformational and compositional discrimination by 14.85 and 14.26 percentage points, estimates conformational populations to within 1.59pp error with a linear probe, and produces particle assignments yielding reference-quality reconstructions in fewer epochs. We demonstrate how to learn representations that capture biological information for use across multiple cryo-EM inverse problems.

Abstract: AI-based cellular perturbation prediction is essential to accelerate drug discovery and therapeutic identification. However, perturbation-specific signals are generally obscured by cellular complexity, making it difficult for existing methods to correctly capture perturbation effects. To address this problem, we propose PerturbEnergy, which introduces a conditional energy-based prior over perturbation representations. It assigns lower energy (higher probability) to representations compatible with the given perturbation and higher energy to others, thereby explicitly tilting the latent space toward perturbation-preferred regions. Besides, PerturbEnergy can be integrated into autoencoder architectures as we find its Evidence Lower Bound (ELBO) is equivalent to the ELBO of the complete autoencoder. We further prove that optimizing PerturbEnergy increases the lower bound on the conditional mutual information between representation and perturbation. Extensive experiments on four benchmark datasets demonstrate the effectiveness of our PerturbEnergy: it improves perturbation recognition especially in latent space with improvement of up to 83.2\%; It also achieves state-of-the-art performance for predicting top-50/100/200 differentially expressed gene(DEG) response and remaining competitive on highly variable gene(HVG) prediction. The code is provided: https://github.com/BlueWhaleLab/PerturbEnergy

Abstract: Predicting single-cell perturbation responses requires mapping between two unpaired populations of cells measured before and after the perturbation. Optimal transport (OT) provides a principled framework for constructing such mappings by minimizing the transport cost, and neural OT methods (\textit{e.g.}, CellOT) have been employed for this prediction task. However, these methods rely on a fixed transport cost, typically the squared Euclidean distance. This cost may connect cells with the wrong responses. Lineage tracing provides the information needed to learn the cost, as heritable barcodes link the cells of the same clone before and after the perturbation. Here, we propose \CloneOT, a neural inverse OT method that learns both the transport cost and the transport map from partially lineage-traced single-cell datasets. \CloneOT\ represents the cost as a neural network. It learns the cost by minimizing the extra cost that the lineage adds to the optimal transport, so that the cheapest transport keeps the cells of each clone together. Our experiments demonstrate that \CloneOT\ recovers the correct transport on 2D datasets, while the squared Euclidean cost fails. Moreover, \CloneOT\ outperforms five baselines on 14 lineage-tracing perturbation scenarios of cancer cells, for both seen and unseen clones. Furthermore, we show that \CloneOT\ reveals the clone-specific transcriptional programs of drug-tolerant persister cells and forecasts the fate of each clone from its cells before treatment. Our implementation is available at https://github.com/poseidonchan/CloneOT.

Abstract: Destructive single-cell measurements provide unpaired population snapshots rather than observations of the same cells across conditions. Local cell states and transition requests may also be insufficient to distinguish responses across source populations. We introduce TempoBridge, a common source-conditioned transport formulation for temporal, genetic, and chemical population transitions. Source cells initialize latent transport and provide a fixed empirical population summary. The velocity field receives this summary alongside the evolving cell state, flow time, and a structured transition descriptor. Minibatch optimal transport (OT) supplies couplings only for conditional flow-matching training paths; inference requires neither target expression nor OT computation. On held-out donors, TempoBridge achieves an Energy distance of 0.129 versus 0.144 for scGen. Genetic mean-expression $L_2$ error is 2.261 versus 3.156 for scGPT-scratch under Seen 2/2. On held-out compounds, condition-averaged drug-effect correlation is 0.598 versus 0.561 for the CellFlow adapter. Temporal ablations show higher mean distributional error after removing source context, replacing optimal transport with random pairing, or replacing flow matching with static residual regression. Together, these results demonstrate the predictive utility of a common source-conditioned transport formulation across held-out donors, gene combinations, and compounds.

Abstract: Generative AI has dramatically accelerated the rate at which new treatments---from novel pharmaceuticals to online marketing campaigns---can be conceived and deployed. As a result, modern experimentation platforms often run continuously, with treatments added as they are ready and removed when they underperform. We formalize this "Always-On" experimental setting, in which treatments can be dynamically generated, added to, and removed from a running experiment, and study the statistical problem of deciding whether to accept or reject each treatment while controlling for the false discovery rate. We develop sequential tests that achieve time-uniform Type-I error control under arbitrary stopping times and "predictable" treatment schedules. Our approach builds on the testing-by-betting framework: we construct test supermartingales for testing the average treatment effect of each treatment, and show that the construction of these test supermartingales is growth-rate optimal in an almost-sure sense.

Abstract: Drug discovery is a costly and high-risk process, where toxicity-related failures remain a major cause of attrition in both preclinical and clinical stages. As a result, accurate early prediction of chemical toxicity is essential to reduce downstream costs and improve compound prioritization. In this context, graph deep learning (GDL) has emerged as a powerful paradigm for toxicity prediction, leveraging molecular graph representations to learn directly from chemical structure with improved expressivity over traditional approaches. Despite the growing number of proposed models, current literature-based comparisons are often difficult to interpret due to inconsistencies in datasets, preprocessing pipelines, and evaluation protocols. To address this limitation, we introduce a unified and standardized benchmarking framework for GDL-based toxicity prediction. We systematically evaluate more than 20 representative approaches under consistent experimental conditions and across multiple datasets and partitioning strategies, enabling a fair and reproducible comparison of model performance. In addition, we complement this empirical study with a structured literature analysis to contextualize existing methodological trends and performance claims. Our results provide a clearer and more reliable assessment of the current state of the field, highlighting both the strengths and limitations of existing graph-based approaches. To support transparency and reproducibility, we release our benchmarking framework as open-source software https://gitlab.citius.gal/noel.suarez/benchtox, allowing the community to evaluate and compare models under consistent conditions.

Abstract: Laboratories often face a new molecular assay with 16-64 labels and a bank of predictors whose training data and parameters are unavailable. The practical question is which frozen outputs to include in a small local model. AssayRouter treats completed assays as pseudo-targets and labels each candidate by its post-fit utility: the reduction in held-out discovery loss when the candidate is added to the local target predictor. A shared regressor learns to predict this utility from candidate behavior on the support set, without source identity; on a new assay, one frozen ranking selects four sources and separate labels fit a convex combiner. We train only on completed ChEMBL-MT assays and evaluate 24 external regression assays across six frozen interface families. AssayRouter-C lowers strict four-call negative log-likelihood (NLL) by 0.0409 relative to Support-CV@4. Frozen candidate-label permutations confirm that candidate-utility correspondence carries the transferred information, and leave-one-interface-out training shows that the mapping generalizes to unseen predictor families. Completed assays therefore provide transferable supervision for scarce-label routing through frozen prediction interfaces.

Abstract: Understanding how drugs interact with protein targets is fundamental to drug discovery, drug repurposing and the early identification of promising therapeutic candidates before costly experimental testing. Sequence-based DTI models face three practical limitations: labelled interactions are scarce and unevenly distributed, large pretrained chemical and protein encoders are expensive to fine-tune end-to-end, and independently encoded sequences do not capture pair-specific dependencies. We present BERT4DTI, which encodes SMILES strings with ChemBERTa and amino-acid sequences with ProtBERT, applies bidirectional mutual attention between token-level representations, and classifies the resulting interaction features using convolutional layers and a multilayer perceptron. To reduce trainable size, ProtBERT is truncated to 18 retained layers and only the last two layers of each encoder are fine-tuned. On BIOSNAP, DAVIS and BindingDB, BERT4DTI is competitive, achieving the best ROC-AUC and PR-AUC on BIOSNAP and the highest sensitivity on all three benchmarks. An ablation on DAVIS shows that mutual attention improves PR-AUC and specificity. With 125M trainable parameters compared with 353M for full BERT fine-tuning, BERT4DTI provides a favourable performance-parameter trade-off for sequence-based DTI screening, while leaving runtime profiling, calibration and leakage-audited validation for future work.

Abstract: This paper presents a novel approach to infer protein topology using the state-of-the-art graph neural network (GNN), SchNet. The model is trained on the same dataset used to develop the recent DeepTMHMM model with 5-fold cross-validation. Unlike the conventional approaches based on using only the protein sequences or the $α$-carbons as features, we have decoded our classifier in this way, so all atom-level embeddings are used. Without applying any pre-trained weight, the final results have shown great potential that GNNs can be used for topological predictions.

Abstract: Recent advancements in image-based profiling techniques have enabled the collection of high-volume cell morphology data, allowing new molecular embedding models to learn from the experimental phenotypic perturbations of a molecule in a cell. Previously, we developed Molecule-Morphology Contrastive Pretraining (MoCoP), a strategy for aligning small molecule embeddings to morphology fingerprints extracted through CellProfiler. The resulting molecular representation showed transferable performance for quantitative structure--activity relationship (QSAR) prediction tasks. Here, we extend the method by using a deep-learning-based cell image encoding pipeline to extract more feature-rich morphology profiles and align them to the molecular embeddings through contrastive learning. The new embeddings encode more accurate information on how molecules perturb cell morphology and enable improvements for QSAR predictions through either fixed-embedding linear probes or fully flexible fine-tuning. Morphology retrieval performance scales log-linearly with training data size, suggesting continued improvements as larger datasets become available. The improved MoCoP v2 also achieves superior performance on toxicity prediction and competitive results on ADME and activity benchmarks, when compared with existing molecular embedding models that use both cell morphology and transcriptomic data during training.

Abstract: Ligand-based virtual screening (LBVS) is a practical first-pass tool in early-stage drug discovery, but existing benchmarks can overestimate performance through random negatives, easy decoys, limited target coverage, and non-standardized evaluation protocols. We introduce TopU-LBVS, a multi-target benchmark for LBVS under hard-negative screening conditions. Starting from curated ChEMBL~35 bioactivity data, TopU-LBVS covers 93 protein targets across 7 protein classes and constructs target-specific screening libraries with property-matched, structurally similar decoys at a fixed 1:40 active-to-decoy ratio. Libraries contain roughly 400 to 10,000 compounds and are designed to reduce simple physicochemical and nearest-neighbor fingerprint shortcuts. TopU-LBVS provides three fixed protocols. TopU-LBVS-full evaluates ChEMBL$^\ast \rightarrow$ TopU generalization across all 93 targets. TopU-LBVS-low evaluates low-data TopU $\rightarrow$ TopU learning within the hard-negative distribution. TopU-LBVS-mini provides a compact seven-target protocol with a paired random-decoy control that changes only the test decoys, enabling low-cost development and direct measurement of the gap between random ChEMBL$^\ast$ and TopU decoys. Across ten reference baselines spanning fingerprint methods, molecular GNNs, fingerprint hybrids, and modern molecular models, performance under random-decoy evaluation degrades sharply under hard-negative screening. We release data, fixed splits, evaluation code, and baseline implementations for reproducible comparison of future LBVS and molecular representation learning methods. Code and data are available at https://github.com/topu-benchmark/topu-lbvs and https://huggingface.co/datasets/topu-benchmark/topu-lbvs.

Abstract: Predicting blood-brain barrier (BBB) permeability is critical for central nervous system drug discovery. Using the MoleculeNet BBBP dataset (n = 2039), this study systematically ablates molecular feature spaces to isolate featurisation from model architecture. We evaluate three feature families (Morgan fingerprints, RDKit physicochemical descriptors, SMILES bigrams) across four learning algorithms. Results demonstrate that predictive performance depends jointly on feature representation and algorithm. Dynamic Random Forest using combined features achieved the highest mean AUC (0.970, 95% CI: 0.963-0.977). Second, this optimal representation enables exploratory estimation of heterogeneous associations between molecular structure and BBB permeability using Generalized Random Forests. Constructing a pseudo-treatment from a LogP median split, we applied double/debiased machine learning to account for confounding. Orthogonalization substantially attenuates the heterogeneity detected by naive causal forests; no conditional effects remained significant after false discovery rate correction (smallest adjusted p = 0.082). Furthermore, orthogonalized feature importance shifted toward residual structural information in SMILES bigrams. Ultimately, once observed confounding is properly accounted for, evidence that LogP-BBB associations vary systematically across chemical space is insufficient. This underscores that feature representation and model architecture are coupled design choices, and that unorthogonalized causal forests risk overstating genuine treatment effect heterogeneity.

Abstract: Scientific research is a continuous process that emphasizes inheritance. Methods developed by predecessors are often expanded upon by new researchers to explore more novel and in-depth scientific questions. However, the change of lab staff, such as student graduation, leads to a lack of personnel capable of replicating methods. Methods that have been developed with significant effort and resources cannot be continued. To address these limitations, we propose LabAgent, a reproduce and discovery harness tailored for a lab's continuous work. LabAgent employs two mechanisms to guarantee that all skills can be executed and verified and to record the corrective methods and experiences, allowing for direct correction or avoidance of similar errors. We applied LabAgent to drug property prediction, biomedical problem analysis, protein variant effect prediction, and statistical genetics in life science domains. LabAgent ranks first over commercial generalist agents in every domain, and demonstrates accurate reproduction of a published figure. Overall, these results demonstrate that LabAgent can effectively integrate and reasonably expand laboratory knowledge.

Abstract: Conformal prediction provides distribution-free uncertainty quantification under exchangeability. However, this assumption is violated by label shift, where the marginal distribution of labels changes while the conditional distribution of inputs given labels remains stable. Under such shifts, standard conformal procedures no longer maintain their intended coverage behavior. Existing approaches address this via importance weighting. They pair the reweighting with residual-based nonconformity scores that ignore predictive uncertainty. The resulting intervals have uniform width. Bayesian conformal methods produce adaptive intervals by leveraging predictive distributions. They evaluate conformity under the source predictive, which is misaligned with the target domain under label shift. We propose the \emph{Label-Shift-Adjusted Bayesian Score} (LSA score), a nonconformity score derived from a posterior predictive tilting identity. This identity shows that the target predictive is an importance-weighted transformation of the source predictive. We use it to derive a direct correction to the Bayesian score. We evaluate the method on molecular property prediction under controlled label shift. The LSA score consistently yields shorter intervals than residual-based and source-based Bayesian scores. Coverage in the target domain remains comparable. Under stronger shift, all methods incur some coverage loss due to pseudo-label-based density-ratio estimation. The LSA score is defined for any source predictive with a tractable log-density. We instantiate it with Bayesian Ridge Regression, where the correction admits a closed form.

Abstract: Designing effective chemotherapy regimens is hindered by tumor heterogeneity and drug resistance, which complicate the deployment of patient-specific model-based optimal control across diverse populations. We develop and compare closed-loop deep reinforcement learning (DRL) dosing policies with continuous (TD3) and discrete (DQN) action spaces trained on a high-dimensional heterogeneous tumor model. The DRL policies are benchmarked against a Pontryagin's Maximum Principle (PMP)-derived open-loop benchmark. We assess generalization under parametric heterogeneity using a 100-patient virtual cohort with plus or minus 10 percent uniform perturbations in growth and drug-sensitivity parameters. Across this cohort, TD3 achieves higher average tumor reduction, while DQN yields tighter inter-patient dosing consistency, revealing a clear efficacy-consistency trade-off in this study. Our simulations assume full observation of all tumor subpopulations; translation to sparse and noisy clinical measurements will require partial-observability formulations and/or state estimation. Overall, the results show that simulation-trained DRL can learn state-dependent feedback dosing policies that complement open-loop optimal control benchmarks.